Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis - Wikidata - awgldk - TriplyDB

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

http://www.wikidata.org/entity/Q24240567

about

Helminth therapy (worms) for induction of remission in inflammatory bowel disease Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis Helminths for induction of remission in inflammatory bowel disease Current approaches to the management of new-onset ulcerative colitis.Current and emerging drugs for the treatment of inflammatory bowel disease.Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis Second Korean guidelines for the management of ulcerative colitis.Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease.Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.Nanotechnology in the treatment of inflammatory bowel diseases.Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.Navigating the complexity of ulcerative colitis: challenging case example.Evidence-based clinical practice guidelines for inflammatory bowel disease.Inhibition of matrix metalloproteinase-9 by a barbiturate-nitrate hybrid ameliorates dextran sulphate sodium-induced colitis: effect on inflammation-related genes.Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases

P2860

Q24201067-67F0343B-04BF-43E5-94A2-8BA7603D62D0 Q24202978-72AEAFAC-014C-490A-B471-044397F05A39 Q24234013-6346CCCC-6E5C-4922-8937-C13001B1BE18 Q33633288-9638191C-78DE-490C-AA7D-11FFF8274B22 Q34883210-2F4DFECD-33B2-4962-9ED0-39B4B7AA12DC Q36210189-5B1B5807-2476-4519-BDAE-777E970E2F9F Q37662503-B93CB61D-EBE3-49A2-A951-4705622E2C6F Q37682512-31A63C22-7E35-4062-B84E-ABAAE8086F0A Q37850826-FF2D0BF5-FA5E-4C39-B873-4B73573453C4 Q38200842-07A2A15A-BDC4-498C-B6BB-BDCD7F433F18 Q42414887-6662EFCF-7B7C-455C-B02F-20DAD9BCEBCB Q42648170-ECBC10CF-2A9E-43EB-B7F9-D5A554E6A76B Q50079201-25366A37-B392-4F2A-81F7-751F74986EEF Q51197180-B4E48268-50E2-4B25-B095-40D6AE37FAB3 Q57167308-222ECD6D-4F16-4FFB-9D7C-390D530C948F

P2860

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

http://www.wikidata.org/entity/Q24240567

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

@ast

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

@en

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

@en-gb

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

@nl

type

label

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

@ast

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

@en

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

@en-gb

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

@nl

prefLabel

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

@ast

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

@en

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

@en-gb

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

@nl

P1433

Q24240567-C8AF136C-0BCD-4035-AA71-A49BF6B7C4AA

P1476

Q24240567-DFD476D5-8024-42A8-840E-36E612FCC6C3

P2093

Q24240567-04BEF807-4C4D-4E47-B6EB-A59B0F6B66C8

Q24240567-40267A03-2AF2-4CA4-9775-2CD4175DA7EE

Q24240567-4068E7F9-5D55-4924-9DAD-227EE800E372

Q24240567-59F4FE87-887D-4D24-B3CB-0E143293AE1F

Q24240567-7A41AFAA-BB5C-4744-957C-C18106BE837B

Q24240567-941BF276-DBB0-4E66-BA47-6E62E4CBE666

P2860

Q24240567-07B81601-48CE-481F-84CB-315E066B8CF9

Q24240567-28988950-C123-4FD8-910A-DAFA8EA34CAF

Q24240567-33276803-782C-4DD6-88CA-630712ACF86C

Q24240567-38172D47-88FB-4C74-AD9D-8BBD318D9659

Q24240567-3B23498C-6B36-4EAD-8119-02618FB62274

Q24240567-408F0AF4-D86E-439A-9FDD-AF767368F7A6

Q24240567-482258F6-0700-4028-ADE6-8DF1AECEBF24

Q24240567-4A05094F-D9C0-4912-B819-BA38F348DDA6

Q24240567-50FEC1E1-C4AD-4FD0-A8E6-A34D02C0391C

Q24240567-52559848-F041-4A1A-AE59-1FB9B8784F6F

P31

Q24240567-9ECBD1B7-CA24-41E6-B968-C0FF2E0EE406

Q24240567-c6291f22-0235-4695-b192-69ae7f92abd3

P3181

Q24240567-F304D524-2EA7-436F-A537-C4E7B0435211

P356

Q24240567-805CF2EF-58CE-4E37-9580-AF72F760FABB

P577

Q24240567-0D114A12-18A8-4FAE-BB38-7ADBC0B465FF

P5875

Q24240567-2930A6E1-E00A-43E0-AF7D-2B8360116354

P698

Q24240567-344414BB-963D-4138-A7E9-EEF8DE62A464

P3181

P356

14651858.CD004115.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis

@en

P2093

A Hillary Steinhart

http://www.w3.org/2001/XMLSchema#string

Anju Anand

http://www.w3.org/2001/XMLSchema#string

E Jan Irvine

http://www.w3.org/2001/XMLSchema#string

Jamie R Newman

http://www.w3.org/2001/XMLSchema#string

John K Marshall

http://www.w3.org/2001/XMLSchema#string

Marroon Thabane

http://www.w3.org/2001/XMLSchema#string

P2860

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.

Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial.

Microscopic activity in ulcerative colitis: what does it mean?

Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis

A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.

Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone foam

Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine

Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis.

P31

scholarly article

P3181

4581171

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/14651858.CD004115.PUB2

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41103875

http://www.w3.org/2001/XMLSchema#string

P698

20091560

http://www.w3.org/2001/XMLSchema#string